HIV Treatment
AIDS 2016: Dolutegravir Plus Lamivudine Works Well as First-Line HIV Treatment
- Details
- Category: HIV Treatment
- Published on Sunday, 24 July 2016 00:00
- Written by Liz Highleyman
A 2-drug regimen of dolutegravir and the well-tolerated NRTI lamivudine led to sustained viral suppression for most people starting antiretroviral therapy (ART) for the first time in a small pilot study, according to a late-breaker presentation at the 21st International AIDS Conference (AIDS 2016) last week in Durban.
AIDS 2016: Long-Acting Injectable Drugs Work Well for HIV Maintenance Therapy
- Details
- Category: Experimental HIV Drugs
- Published on Thursday, 21 July 2016 00:00
- Written by Liz Highleyman
A pair of long-acting injectable antiretrovirals -- cabotegravir and rilpivirine -- administered once every 4 or 8 weeks maintained viral suppression in people who switched regimens with undetectable viral load, according to 48-week results from the LATTE-2 trial presented at the 21st International AIDS Conference (AIDS 2016) this week in Durban. A related qualitative analysis showed that study participants preferred long-acting injectables over pills for several reasons.
AIDS 2016: Gains in Curbing HIV Could Be Lost Without Continued Commitment
- Details
- Category: HIV Treatment
- Published on Monday, 18 July 2016 00:00
- Written by Liz Highleyman
Participants at the 21st International AIDS Conference (AIDS 2016), taking place this week in Durban, South Africa, reviewed the remarkable gains that have been made in access to HIV treatment and new prevention tools since the conference was last held here 16 years ago. But researchers, activists, and government leaders agreed that this progress could be reversed if stakeholders do not commit to increased funding and respect for the human rights of key populations at risk.
AIDS 2016: Young Women Treated Very Early Stay HIV Negative and Preserve Immune Function
- Details
- Category: Search for a Cure
- Published on Tuesday, 19 July 2016 00:00
- Written by Gus Cairns
A group of youngSouth African women who were diagnosed during very HIV early infection and immediately given antiretroviral therapy (ART) preserved their CD4 cell counts and the function of cells that HIV normally disrupts, according to a study presented at the 2016 Towards an HIV Cure Symposium, which preceded the 21st International AIDS Conference this week in Durban, South Africa. The majority of them never seroconverted, staying HIV-negative despite having evidence of low levels of HIV infection in their cells.
AIDS 2016: International AIDS Conference Starts Next Week in Durban
- Details
- Category: HIV Treatment
- Published on Tuesday, 12 July 2016 00:00
- Written by Liz Highleyman
The 21st International AIDS Conference (AIDS 2016) opens next Monday, July 18, in Durban, South Africa, 16 years after the groundbreaking conference in the same city that put the spotlight on global access to new life-saving treatment for people living with HIV and AIDS. This year's theme -- Access, Equity, Rights Now -- recognizes the barriers that still need to be overcometo achieve universal access. HIVandHepatitis.comand collaborator Aidsmap.comwill provide on-site coverage starting on July 17. Follow @HIVandHepatitison Twitter and visit our AIDS 2016 conference page (coming soon) or Facebook pagefor the latest news.
More Articles...
- ASM Microbe 2016: Switching from Tenofovir DF to TAF Improves Bone and Kidney Safety
- ART Reduces Opportunistic Illnesses in Children and Adults with HIV
- AIDS 2016: International AIDS Conference Coming Up in Durban
- ASM Microbe 2016: New Integrase Inhibitor Bictegravir Looks Promising in Early Studies
Web Design and Development by